Selected NCI-Supported Trials

ComboMATCH (Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice) is a series of precision medicine cancer treatment clinical trials. These trials will help determine whether treating cancer using combinations of targeted therapies based on specific genetic changes found in people’s tumors is effective.

In this precision medicine clinical trial, children, teens, and young adults with advanced cancers whose tumors have certain genetic changes are being treated with drugs designed to target those mutations.

NCI-MATCH is a precision medicine trial that is no longer enrolling patients. It assigned people with advanced solid tumors and lymphomas to treatment arms based on the molecular profiles of their cancer.

Pragmatica-Lung is a clinical trial for people with non-small cell lung cancer that has spread beyond the lungs (stage 4 cancer). The trial will help confirm if the combination of pembrolizumab and ramucirumab helps people with advanced lung cancer live longer.

A collection of material about the ALCHEMIST lung cancer trials that will examine tumor tissue from patients with certain types of early-stage, completely resected non-small cell lung cancer for gene mutations in the EGFR and ALK genes, and assign patients with these gene mutations to treatment trials testing post-surgical use of drugs targeted against these mutations.

The Lung Cancer Master Protocol, or Lung-MAP, is a precision medicine research study for people with advanced non-small cell lung cancer that has continued to grow after treatment. Patients are assigned to different study drug combinations based on the results of genomic profiling of their tumors.

A collection of material about the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, which will examine whether a molecular test can assign women with early-stage breast cancer to the most appropriate and effective treatment.

TMIST is a randomized breast screening trial that compares two Food and Drug Administration (FDA)-approved types of digital mammography, standard digital mammography (2-D) with a newer technology called tomosynthesis mammography (3-D).

Information about the National Lung Screening Trial (NLST), a research study sponsored by the National Cancer Institute that used low-dose helical CT scans or chest X-ray to screen men and women at risk for lung cancer.

A large-scale clinical trial to determine whether certain cancer screening tests reduce deaths from prostate, lung, colorectal, and ovarian cancer. In addition, there are numerous epidemiologic and ancillary studies going on that will answer other crucial questions about these cancers and these screening tests.

The FORTE study will help determine the best timing for repeat colonoscopy after removal of 1 or 2 small benign polyps during a routine screening colonoscopy. Currently, people with 1 or 2 polyps removed come back for another coloscopy after 5 years. FORTE will randomly assign eligible participants to repeat colonoscopies at 5 and 10 years or just at 10 years.